Faron, etusivu

releases and publications

Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Regulatory

Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Regulatory

Faron’s Financial Statements Release 1 January to 31 December 2025

Regulatory

Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

Regulatory

Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS

Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING

Regulatory

Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones

Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory
Next
Back to top